Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Quadrivalent Influenza Vaccine Gains FDA Approval

XTALKS VITALS NEWS

Vaccine

According to a press release issued by the company, Flublok Quadrivalent is the only influenza vaccine approved by the FDA which contains a high antigen content.

Tweetables from this article:

Tweet: #Clinicaltrial: adults given the Flublok Quadrivalent #vaccine had a 40 percent lesser chance of contracting #influenza http://ctt.ec/9dkcZ+ #Clinicaltrial: adults given the Flublok Quadrivalent #vaccine had a 40 percent lesser chance of contracting #influenza.

Share this!

October 13, 2016 | by Sarah Hand, M.Sc.

Protein Sciences Corporation’s quadrivalent Flublok influenza vaccine has been approved by the US Food and Drug Administration (FDA). This latest version of the influenza vaccine protects against three of the same strains found in the previous trivalent Flublok, in addition to a fourth B strain of the virus.

According to a press release issued by the company, Flublok Quadrivalent is the only influenza vaccine approved by the FDA which contains a high antigen content. The vaccine is well-suited to the elderly and those with a compromised immune system as it contains three times more of the active ingredient, compared to other approved quadrivalent vaccines.



To test the efficacy of Flublok Quadrivalent in people over the age of 50, Protein Sciences conducted a 9,000 participant clinical trial. They found that adults given the Flublok Quadrivalent had a 40 percent lesser chance of contracting influenza, compared to those that were administered the leading quadrivalent vaccine.

“The U.S. has been trending toward the use of quadrivalent flu vaccines in recent years,” said Manon Cox, President and CEO of Protein Sciences Corporation. “We are pleased to bring Flublok Quadrivalent to market to give consumers additional options, especially seniors who have no other high antigen content quadrivalent vaccine available to them. We are looking forward to launching the vaccine next year and, in the meantime, continuing to make trivalent Flublok available this year.”

Flubok Quadrivalent has been approved by the FDA for use in patients 18 and older and will be available in early 2017. As a protein-based vaccine, it contains no infectious influenza virus, antibiotics, egg products or preservatives. Approved in 2013, the trivalent version of the vaccine is available in pharmacies throughout the US.


Keywords: Influenza, Vaccine, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.